Alzheimer's Society
This sponsor has funded 4 studies across 2 countries.
| EU PAS ID | Status | RMP requirement | Title | Protocol uploaded | Results uploaded |
|---|---|---|---|---|---|
| 8705 | Ongoing | Not included in RMP | Benzodiazepine and anticholinergic use and incident dementia (ABCD study) | No | No |
| 23753 | Planned | Not included in RMP | Longitudinal Analyses of Blood Pressure and Risk of Alzheimer´s disease and Vascular Dementia in 2.6 million people over 2 decades (BP and Dementia) | No | Yes |
| 23959 | Planned | Not included in RMP | Longitudinal Analyses of Blood Lipids and Future Risk of Dementia in CPRD (Lipids and dementia) | Yes | No |
| 43447 | Ongoing | Not included in RMP | Overactive bladder anticholinergics and risk of incident dementia: a cohort study design using a triangulation approach | No | No |
PAS by Risk Management Plan (RMP) requirement
Alzheimer's Society
The RMP for a medical product outlines strategies to identify, assess, and mitigate risks, including PAS for further evaluation.
Category 1 studies are imposed as condition of marketing authorisation.
Category 2 studies are imposed as specific obligation of marketing authorisation.
Category 3 studies are required under other circumstances.
PAS by study status
Alzheimer's Society
The study status is defined according to the timeline dates specified.
Planned studies have not collected any data yet.
Ongoing studies collect data and should publish protocols as soon as possible.
Finalised studies should publish results in the first two weeks after finalisation.
Countries
Alzheimer's Society
2 Study countries specified are the following:
- Spain
- United Kingdom